Gemfibrozil in the Treatment of Dyslipidaemia A 5-year follow-up study
| Autor: | P. Kuusisto, Vesa Manninen, Marjatta Mälkönen, J. Virtamo, Antti Eisalo, Jaakko Tuomilehto |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
5 year follow up Cirrhosis Cholesterol VLDL Population Myocardial Infarction Lipoproteins VLDL 030204 cardiovascular system & hematology Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Valerates Internal Medicine medicine Humans Gemfibrozil 030212 general & internal medicine Myocardial infarction Pentanoic Acids education Hypolipidemic Agents Ldl cholesterol Clinical Trials as Topic education.field_of_study Cholesterol business.industry Cholesterol HDL nutritional and metabolic diseases Cholesterol LDL Lipid Metabolism medicine.disease Coronary heart disease 3. Good health Lipoproteins LDL Endocrinology chemistry lipids (amino acids peptides and proteins) Lipoproteins HDL business Follow-Up Studies medicine.drug |
| Zdroj: | Acta Medica Scandinavica. 212:82-87 |
| ISSN: | 0001-6101 |
| DOI: | 10.1111/j.0954-6820.1982.tb08526.x |
| Popis: | The efficacy and safety of gemfibrozil in treating dyslipidaemias was investigated in a 5-year follow-up study of 254 patients with primary dyslipidaemias. Most were middle-aged males of type IIA or IIB. A significant correction of serum lipid level was seen in about 90% of dyslipidaemias, irrespective of the type. It was not possible to find a clear cause for non-responsiveness, although cirrhosis of the liver was suggested in some cases. Overall, gemfibrozil decreased serum total cholesterol by 16% LDL cholesterol by 23% and the triglyceride level by 40%; HDL cholesterol rose by 23% and HDL cholesterol as percentage of total cholesterol from 14.3% to 20.8% to approach the value of matched controls in the population without dyslipidaemia (24.2%). Side-effects were few. Among the treated subjects the observed number of myocardial infarctions was much less (4 vs 14) than expected. This by no means proves that gemfibrozil will prevent myocardial infarction, but is evidence to support that raising HDL and lowering LDL may give clinical benefit in the prevention of coronary heart disease. A more substantial primary prevention study in a population of patients at high risk, i.e. middle-aged males with dyslipidaemia, is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|